AbCellera Biologics Inc vs Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 — how do they compare? AbCellera Biologics Inc trades at $9.09 (market cap $2.85B), while Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 trades at $45.01. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 nearer its low. Which is the better fit depends on your goals.
| ABCL | USOI | |
|---|---|---|
Market Cap | $2.85B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $9.76 | $61.17 |
52-Week Low | $2.78 | $42.27 |
Enterprise Value | $2.45B | — |
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
USOI (Credit Suisse X-Links Crude Oil Shares Covered Call ETN) trades at $45.05, up 0.2% with a bearish technical signal from moving averages. The ETN provides exposure to oil-linked covered call strategies, generating high yields but with complex risk exposure. Recent coverage highlights its unique structure and high yield potential amid shifting market dynamics.
The outlook remains cautious given the bearish technical setup and complex ETN structure. While the high yield strategy offers income potential, investors face significant commodity price volatility and counterparty risk. The lack of traditional equity fundamentals requires careful risk assessment of the underlying oil exposure and issuer creditworthiness.
Trailing returns across standard periods
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →USOI is an Exchange-Traded Note (ETN) issued by UBS that provides exposure to a covered call strategy on the United States Oil Fund (USO). It aims to generate high monthly income by capturing option premiums from the hypothetical sale of out-of-the-money call options on oil shares, offering a way to profit from crude oil's volatility even in a flat or range-bound market.
Read more on USOI →